Lower is better: Implications of the Treating to New Targets (TNT) study for Canadian patients

Canadian Journal of Cardiology

Volumn 22, Issue 10, 2006, Pages 835-839

  Fitchett, David H ^a   Leiter, Lawrence A ^a   Goodman, Shaun G ^a   Langer, Anatoly ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cholesterol; Coronary disease; Lipids

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

CANADA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LIVER DYSFUNCTION; META ANALYSIS; MONOTHERAPY; PATIENT COMPLIANCE; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DYSLIPIDEMIA; HEART INFARCTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SUDDEN DEATH;

ANTILIPEMIC AGENTS; CANADA; CEREBROVASCULAR ACCIDENT; CHOLESTEROL, LDL; DEATH, SUDDEN, CARDIAC; DYSLIPIDEMIAS; HEPTANOIC ACIDS; HUMANS; MYOCARDIAL INFARCTION; PYRROLES; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 33749049339     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(06)70301-4     Document Type: Article

References (28)

1. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men. Lancet 1986;2:933-6.
2. Dawber TR, Kannel WB. The Framingham Study. An epidemiological approach to coronary heart disease. Circulation 1966;34:553-5.
3. Assman G, Schulte H, Cullen P. New and classical risk factors - the Munster heart study (PROCAM). Eur J Med Res 1997;2:237-42.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
6. Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo controlled trial. Lancet 2002;360:7-22.
7. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
8. The Long-Term Intervention with Pravastatin in Ischemic Heart Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
10. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
11. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60.
12. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (Version current at July 6, 2006).
13. Genest J, Frohlich J, Fodor G, McPherson R; Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 2003;169:921-4.
14. Nissen SE, Tuzcu EM, Schoenhagen P, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-80.
15. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001;357:577-81.
16. Nissen SE, Nicholls SJ, Sipahi I, et al; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006;295:1556-65.
17. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
18. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. N Engl J Med 2005;352:1425-35.
19. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6.
20. Hackam DG, Tan MK, Honos GN, Leiter LA, Langer A, Goodman SG; Vascular Protection registry investigators. How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Ptotection (VP) Registry. Am Heart J 2004;148:1028-33.
21. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after acute myocardial infarction: The IDEAL Study: A randomized controlled trial. JAMA 2005;294:2437-45.
22. Keech A, Simes RJ, Barter P, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes (the FIELD study): Randomised controlled trial. Lancet 2005;366:1849-61.
23. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
24. Fitchett DH, Leiter LA, Tardif JC, Goodman S, Langer A. Are Canadian guidelines for cholesterol lowering in high-risk patients optimal? Can J Cardiol 2005;21:85-90.
25. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
26. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002;18(Suppl 3):S82-5.
27. Yan AT, Yan RT, Tan M, et al; Vascular Protection (VP) and Guideline Oriented Approach to Lipid Lowering (GOALL) registries investigators. Contemporary managment of dyslipidemia in high-risk patients: Targets still not met. Am J Med 2006 (In press).
28. Martineau P, Gaw A, de Teresa E, et al; on behalf of the ACTFAST investigators. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis 2006. [Epub ahead of print]